PARP Inhibitor Plus Temozolomide Shows Promise in Relapsed Small-Cell Lung Cancer Trial
A phase Ib/II trial in China found that the oral PARP inhibitor HTMC0435 combined with temozolomide produced a manageable safety ...
A phase Ib/II trial in China found that the oral PARP inhibitor HTMC0435 combined with temozolomide produced a manageable safety ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine